Alimera faces NICE set back with Iluvien
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has issued draft guidance declining to recommend Alimera's Iluvien (fluocinolone acetonide) for treating chronic diabetic macular oedema (DMO). The manufacturer's economic modelling fell short, while the firm had not submitted evidence that accurately reflected clinical practice, said the institute.